JTO Clinical and Research Reports, April 2023, Volume 4, Issue 4
Journal | English
Image For Activity Cover
Credit Offered
No Credit Offered
Table of Contents

  • Uncommon EGFR-Mutant NSCLC - One Drug Does Not Fit All
Original Articles:
  • Long-Term Outcomes After Chemoradiotherapy and Surgery for Superior Sulcus Tumors
  • First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
  • Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
  • Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study
  • Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC
  • Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study
  • LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
  • Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases
  • Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial
  • TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study
  • Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors
Case Reports
  • Thoracic SMARCA4-Deficient Undifferentiated Tumor With ALK Fusion Treated With Alectinib Achieved Remarkable Tumor Regression: Case Report
  • ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
  • Capillary Leak Syndrome With Pulmonary Edema Preceded by Organizing Pneumonia Caused by Combination Therapy With Nivolumab and Ipilimumab: A Case Report
  • Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal NTRK1 Fusion: Case Report
Brief Reports
  • Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors
  • Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
  • Brief Report: Prognostic Relevance of 3q Amplification in Squamous Cell Carcinoma of the Lung
  • Racial, Ethnic, and Socioeconomic Characteristics Independently Predict for Cachexia Risk and Associated Survival Outcomes in Stage IV NSCLC: A Brief Report
  • Biopsy Method and Needle Size on Success of Next-Generation Sequencing in NSCLC: A Brief Report
Review Article
  • Programmed Cell Death Protein 1 Inhibitor-Mediated Peripheral Neuropathy
JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing the following article types in particular:
  • Phase I trials
  • Well performed single-arm phase II trials
  • Subset analyses of published trials
  • Impactful retrospective Studies
  • Database analysis
  • Large institutional series
  • High-quality case reports
  • Region-specific clinical trials
  • Subspecialty thoracic oncology studies
  • Selected high-quality meeting reports
As an open access journal with no subscription charges, JTO CRR requires authors to pay a fee to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone.
Powered By